Quick Answer
Vanda Pharmaceuticals Inc. reported Cash and Equivalents of $84.85 million for fiscal year 2025.
Vanda Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $84.85M | -17.1% |
| 2024 | $102.32M | -24.7% |
| 2023 | $135.82M | +0.6% |
| 2022 | $135.03M | +159.3% |
| 2021 | $52.07M | -14.7% |
| 2020 | $61.03M | +35.4% |
| 2019 | $45.07M | -26.1% |
| 2018 | $61.01M | +81.4% |
| 2017 | $33.63M | -16.8% |
| 2016 | $40.43M | -20.5% |
| 2015 | $50.84M | -16.5% |
| 2014 | $60.90M | -6.0% |
| 2013 | $64.76M | -27.0% |
| 2012 | $88.77M | +1.0% |
| 2011 | $87.92M | +106.6% |
| 2010 | $42.56M | -79.3% |
| 2009 | $205.29M | +425.3% |
| 2008 | $39.08M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $70.02M | -30.3% | -13.5% |
| June 30, 2025 | $80.98M | -21.3% | -27.6% |
| March 31, 2025 | $111.80M | -10.7% | +9.3% |
| December 31, 2024 | $102.32M | -24.7% | +1.8% |
| September 30, 2024 | $100.50M | -45.1% | -2.4% |
| June 30, 2024 | $102.95M | -31.4% | -17.7% |
| March 31, 2024 | $125.16M | -64.7% | -7.9% |
| December 31, 2023 | $135.82M | +0.6% | -25.9% |
- Vanda Pharmaceuticals Inc. showed a decrease of -17.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, Vanda Pharmaceuticals Inc.’s cash and equivalents has grown by 117.1% (from $39.08 million to $84.85 million).
- The most recent figure is from Vanda Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: